Wiersinga WM - This overview intended to assess current establishments in the field of T4+T3 therapy. As per the results, these biomarkers advoacated euthyroidism more frequently in patients randomized to T4+T3 rather than to T4. Moreover, preference for T4+T3 over T4 monotherapy was dose-dependently related to the presence of two polymorphisms in MCT10 and DIO2 in one small study. The number of patients on T4+T3 therapy has multiplied in the last decade, likely induced by indiscriminate statements on the internet. In addition, patients are sometimes not just asking but rather demanding T4+T3 treatment.